Videos

IABS Bioaster – FMT WEBINAR

Watch the replay of the presentation by Our CEO Herve Affagard, MBA, Eng., during the…

MaaT PharmaJune 2, 2021

Press ReleasesScientific Publications

MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications

The trial of the autologous microbial therapy, MaaT011, met its primary endpoints through demonstration of…

MaaT PharmaMay 25, 2021

Videos

EY : Prix de l’Entrepreneur de l’Année

Découvrez ci-dessous l'intervention de notre CEO Herve Affagard, MBA, Eng. pour le Prix de l'Entrepreneur de…

MaaT PharmaMay 5, 2021

Videos

Hybridays 2021: Savita BERNAL, Chief Business Officer at MaatPharma

Our Chief Business Officer Savita Bernal attended HYBRID 2021, on March 16th, an event focused this…

MaaT PharmaApril 28, 2021

Press Releases

Lancement de l’Alliance Promotion Microbiote

Communiqué de presse Lancement de l’Alliance Promotion Microbiote Le 29 mars 2021 – L’Alliance Promotion…

MaaT PharmaMarch 29, 2021

Press Releases

MaaT Pharma annonce des premiers résultats positifs dans l’essai clinique de phase 2 HERACLES avec MaaT013 chez les patients atteints d’une maladie du greffon contre l’hôte aiguë (aGvHD)

L'étude atteint ses objectifs clés, principaux et secondaires, avec un impact clinique positif et une…

MaaT PharmaMarch 17, 2021

Press Releases

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

Study meets primary and key secondary objectives with positive impact and favorable overall safety profile…

MaaT PharmaMarch 17, 2021

Press Releases

MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Data from 29 patients in the company’s early access program with MaaT013 as a treatment…

MaaT PharmaMarch 11, 2021

Press Releases

MaaT Pharma Announces First Positive DSMB Safety Review for Phase Ib CIMON Trial Testing Its Microbiome Ecosystem Therapy Capsule Formulation in AML Patients

Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of…

MaaT PharmaDecember 22, 2020

Press Releases

MaaT Pharma Presents Positive Updated Results with its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute GvHD at ASH 2020 Annual Meeting

Data showed MaaT013 to be safe and effective in 29 heavily pre-treated and immunocompromised gastrointestinal…

MaaT PharmaDecember 7, 2020